A Long-Term, Open-Label, Prospective Phase IV Study to Assess the Safety and Efficacy of Nephoxil in Subjects With End Stage Renal Disease (ESRD) on Dialysis
Phase of Trial: Phase IV
Latest Information Update: 18 Jun 2019
Price : $35 *
At a glance
- Drugs Ferric citrate (Primary)
- Indications Hyperphosphataemia
- Focus Adverse reactions
- Sponsors Panion & BF Biotech
- 13 Jun 2019 Status changed from active, no longer recruiting to completed.
- 27 Mar 2019 Planned End Date changed from 31 Jan 2019 to 31 May 2019.
- 31 Aug 2018 Biomarkers information updated